Kodiak Sciences (KOD) Cash from Financing Activities (2017 - 2026)
Kodiak Sciences (KOD) posted Cash from Financing Activities of $619000.0 for Q1 2026, down 99.65% on a QoQ basis from $177.2 million in Q4 2025, and up 399.19% year-over-year from $124000.0 in Q1 2025.
Kodiak Sciences (KOD) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Kodiak Sciences' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $619000.0 for Q1 2026.
- Quarterly Cash from Financing Activities rose 399.19% year-over-year to $619000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.8 million (up 30359.45% YoY) and the FY2025 annual result came in at $178.3 million, up 35489.22% from the prior year.
- Cash from Financing Activities was $619000.0 for Q1 2026 at Kodiak Sciences, down from $177.2 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $177.2 million in Q4 2025 and bottomed at -$124000.0 in Q4 2023.
- A 5-year average of $11.3 million and a median of $108500.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 227.84% — and 2025, when it soared 43772.52%.
- Kodiak Sciences' Cash from Financing Activities stood at $97000.0 in 2022, then plunged by 227.84% to -$124000.0 in 2023, then jumped by 425.81% to $404000.0 in 2024, then surged by 43772.52% to $177.2 million in 2025, then plunged by 99.65% to $619000.0 in 2026.
- Business Quant data shows KOD's Cash from Financing Activities at $619000.0 in Q1 2026, $177.2 million in Q4 2025, and $813000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Kodiak Sciences | 2.54 Bn | 2.54 Bn | - | 619,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 619,000.00 |
| Mar 31, 2026 | 619,000.00 |
| Dec 31, 2025 | 177.25 Mn |
| Dec 31, 2025 | 177.25 Mn |
| Sep 30, 2025 | 813,000.00 |
| Sep 30, 2025 | 813,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 124,000.00 |
| Mar 31, 2025 | 124,000.00 |
| Dec 31, 2024 | 404,000.00 |
| Dec 31, 2024 | 404,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Dec 31, 2023 | -124,000.00 |
| Dec 31, 2023 | -124,000.00 |
| Sep 30, 2023 | -12,000.00 |
| Sep 30, 2023 | -12,000.00 |